A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary Evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous Anti-human Interleukin-5 (Mepolizumab, 750mg and 1500mg) in the Treatment of Eosinophilic Oesophagitis in Adults
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Mepolizumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Pharmacodynamics
- 05 Jun 2012 New source identified and integrated: ClinicalTrials.gov record NCT00274703.
- 05 Nov 2010 New trial record.